Merck KGaA's large-scale partnering

Merck KGaA's deal with GlaxoSmithKline plc to develop cancer therapy M7824 enables Merck to pursue a more ambitious development plan than it could have done by going it alone, and provides a template for how it may bring similarly broad programs to market going forward.

The deal marks the second time in the past five years Merck has sought out a large pharma partnership for a high value asset as a means to maximize its value and reach, as quickly as possible. ...